focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 311.50
Bid: 308.00
Ask: 311.50
Change: 7.00 (2.30%)
Spread: 3.50 (1.136%)
Open: 307.00
High: 312.50
Low: 300.00
Prev. Close: 304.50
SYNT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Pricing of senior notes

12 Apr 2024 07:00

RNS Number : 3607K
Synthomer PLC
12 April 2024
 

April 12, 2024

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO

 

SYNTHOMER PLCPRICING OF SENIOR NOTES

Synthomer plc ("Synthomer") today announces that it has priced its offering (the "Offering") of €350 million in aggregate principal amount of senior notes due 2029 (the "Notes") at a coupon of 7⅜%.

The Notes will be unconditionally guaranteed by certain of Synthomer's subsidiaries. Synthomer intends to use the proceeds from this Offering, together with cash on balance sheet, to (i) repurchase or redeem certain of its existing 3⅞% senior notes due 2025 (the "Existing Notes") and (ii) pay certain costs, expenses and fees relating to the Offering.

The Offering is expected to close on or about April 18, 2024, subject to customary conditions precedent for similar transactions.

Lily Liu, Synthomer plc Chief Financial Officer, commented: "We are very pleased with the substantial support for this transaction, which represents another major milestone in improving our financial platform, and puts Synthomer in a stronger position to deliver our strategy."

 

 

Cautionary Statement

The Offering is being made by means of an offering memorandum. This announcement does not constitute an offer to sell or the solicitation of an offer to buy the Notes or any other security and shall not constitute an offer, solicitation or sale in the United States or in any jurisdiction in which, or to any persons to whom, such offering, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any jurisdiction.

The Notes have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold within the United States, or to, or for the account or benefit of, U.S. persons, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state or local securities laws. Accordingly, the Notes are being offered and sold in the United States only to qualified institutional buyers in accordance with Rule 144A under the Securities Act and to non-U.S. persons outside the United States in accordance with Regulation S under the Securities Act.

Promotion of the Notes in the United Kingdom is restricted by the Financial Services and Markets Act 2000 (the "FSMA"), and accordingly, the Notes are not being promoted to the general public in the United Kingdom. This announcement is only addressed to and directed at persons who (i) are outside the United Kingdom, (ii) have professional experience in matters relating to investments (being investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Financial Promotion Order")), (iii) fall within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations, etc.") of the Financial Promotion Order, or (iv) to the extent that doing so does not prejudice the lawful distribution of the announcement to the foregoing, are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the FSMA) in connection with the issue or sale of any Notes may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as "relevant persons"). The Notes will only be available to relevant persons and this announcement must not be acted on or relied on by anyone who is not a relevant person. No key information document required by Regulation (EU) No 1286/2014 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 (the "EUWA") (the "UK PRIIPs Regulation") for offering or selling the Notes or otherwise making them available to retail investors in the UK has been prepared and, therefore, offering or selling the Notes or otherwise making them available to any retail investor in the UK may be unlawful under the UK PRIIPs Regulation. Any offer of the Notes in the UK will be made pursuant to an exemption under Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the EUWA from a requirement to publish a prospectus for offers of securities.

This announcement does not constitute and shall not, in any circumstances, constitute a public offering nor an invitation to the public in connection with any offer within the meaning of the Regulation (EU) 2017/1129 (as amended), and any relevant implementing measure in the relevant Member State of the European Economic Area (the "Prospectus Regulation"). The offer and sale of the Notes will be made pursuant to an exemption under the Prospectus Directive, as implemented in Member States of the European Economic Area, from the requirement to produce a prospectus for offers of securities.

Manufacturer target market (MIFID II product governance) is eligible counterparties and professional clients only (all distribution channels). No PRIIPs key information document (KID) has been prepared as not available to retail investors in EEA.

This press release may include "forward looking statements" within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. These forward looking statements can be identified by the use of forward looking terminology, including the terms "believes," "estimates," "anticipates," "expects," "intends," "may," "will" or "should" or, in each case, their negative, or other variations or comparable terminology. These forward looking statements include all matters that are not historical facts and include statements regarding Synthomer or its affiliates' intentions, beliefs or current expectations concerning, among other things, the Offering.

By their nature, forward looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Readers are cautioned that forward looking statements are not guarantees of future performance and that Synthomer and its affiliates' actual results of operations, financial condition and liquidity, and the development of the industry in which they operate may differ materially from those made in or suggested by the forward looking statements contained in this press release. In addition, even if Synthomer or its affiliates' results of operations, financial condition and liquidity, and the development of the industry in which the Synthomer operates are consistent with the forward looking statements contained in this press release, those results or developments may not be indicative of results or developments in subsequent periods. Given these risks and uncertainties, you should not rely on forward looking statements as a prediction of actual results.

Statements of intent in this press release shall not constitute a notice of redemption under the indenture governing Synthomer's 3⅞% senior notes due 2025. Any such notice, if made, will only be made in accordance with the provisions of the relevant indenture.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IODDBGDSUBBDGSB
Date   Source Headline
8th Mar 20184:37 pmRNSDirector/PDMR Shareholding
5th Mar 20182:43 pmRNSDirector/PDMR Shareholding
1st Mar 20187:00 amRNSResults for the year ended 31 December 2017
12th Feb 201810:27 amRNSDirector Declaration
1st Feb 20187:00 amRNSCompletion of the acquisition of BASF Pischelsdorf
2nd Jan 20187:00 amRNSDisposal of Synthomer Leuna Gmbh facility
13th Dec 20172:55 pmRNSDirector Declaration
4th Dec 20175:31 pmRNSHolding(s) in Company
27th Nov 20179:29 amRNSHolding(s) in Company
10th Nov 20179:40 amRNSDirectorate Change
9th Nov 201710:03 amRNSDirector/PDMR Shareholding
6th Nov 20177:00 amRNSQ3 Trading update
9th Oct 20179:23 amRNSDirector Declaration
28th Sep 20177:00 amRNSAcquisition of BASF Pischelsdorf
18th Sep 20172:00 pmRNSHolding(s) in Company
17th Aug 201712:54 pmRNSHolding(s) in Company
8th Aug 20177:00 amRNSInterim Results for the 6 months ended 30 Jun 2017
1st Aug 20173:57 pmRNSHolding(s) in Company
10th Jul 201710:33 amRNSDirector/PDMR Shareholding
9th Jun 20173:14 pmRNSDirector/PDMR Shareholding
8th May 201712:40 pmRNSDirector/PDMR Shareholding
8th May 201712:24 pmRNSDirector/PDMR Shareholding
27th Apr 20174:05 pmRNSDirector Declaration
27th Apr 20172:53 pmRNSResult of AGM
27th Apr 20177:00 amRNSQ1 Trading update
27th Mar 20179:54 amRNSAnnual Financial Report
6th Mar 20177:02 amRNSAcquisition of Perstorp Belgium
6th Mar 20177:00 amRNSFinal Results
23rd Feb 20174:31 pmRNSAmendment TR-1 notification
8th Feb 20174:13 pmRNSHolding(s) in Company
6th Feb 201711:48 amRNSHolding(s) in Company
20th Jan 20177:00 amRNSQ4 and FY trading update
13th Dec 201610:57 amRNSHolding(s) in Company
1st Dec 20167:00 amRNSCapital Markets Day
28th Nov 20169:51 amRNSHolding(s) in Company
18th Nov 20164:56 pmRNSHolding(s) in Company
16th Nov 201610:15 amRNSHolding(s) in Company
10th Nov 20162:23 pmRNSHolding(s) in Company
9th Nov 20164:18 pmRNSDirector/PDMR Shareholding
9th Nov 20167:00 amRNSQ3 Trading update
3rd Oct 20162:11 pmRNSHolding(s) in Company
26th Sep 20169:25 amRNSHolding(s) in Company
14th Sep 20163:10 pmRNSHolding(s) in Company
14th Sep 20163:01 pmRNSHolding(s) in Company
11th Aug 20161:15 pmRNSDisposal
9th Aug 20167:00 amRNSInterim Results for six months ended 30 June 2016
7th Jul 201611:50 amRNSHolding(s) in Company
7th Jul 201610:28 amRNSDirector/PDMR Shareholding
5th Jul 201611:57 amRNSHolding(s) in Company
1st Jul 20167:00 amRNSCompletion of acquisition and trading update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.